ImmuPharma Attending Bio-Europe Spring – 17-19 March 2025, Milan

Further opportunities to present recent insights into the MOA* of the P140 technology platform

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CEO of the R&D subsidiary ImmuPharma Biotech will be attending the Bio-Europe Spring Conference from 17-19 March 2025, in Milan.

BIO-Europe Spring is a premier partnering event in the biopharmaceutical and life sciences sector bringing together over 3,700 executives and facilitating more than 20,000 one-on-one meetings. It is an important opportunity for networking among biotech companies, pharmaceutical firms, investors, and academia.

Commenting on attendance at the Bio-Europe Spring conference, Tim McCarthy, CEO of ImmuPharma said: “Following on from positive discussions already held with a number of global BioPharma companies, we are focussed on continuing the momentum towards completing commercial deals across the portfolio.”

 *Mechanism of Action – update announcement issued on 13 March 2025 click here

To download announcement click here